Pasithea Therapeutics Corp.

KTTA Healthcare Biotechnology

EPS
+75.8%
Free cash flow
−21.7%

Quarter to June 2026, against a year earlier

0.58 0.06 +11.54%
Market cap
$17.4M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
n/a
Altman Z
2.97
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(65.49%) (58.22%) (58.36%) (89.90%)

+8 more TTM periods

ROA
(61.97%) (55.58%) (53.54%) (83.64%)
ROIC
(367.46%) (319.73%) 0.00% (108.52%)
Return on Tangible Assets
(45.88%) (38.51%) (39.68%) (325.00%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.55) (0.70) (1.17) (1.65)
Free Cash Flow
(17.78) (16.94) (15.07) (12.26)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026